2. UroToday Home
  3. Video Lectures
  4. mCRPC Treatment
The LuRa Study of Radium-223 After Prior Lutetium-177-PSMA-617 in mCRPC - Kambiz Rahbar
TRITON-3 Safety Analysis of Rucaparib in Post-ARPI Metastatic CRPC - Alan Bryce
Crossover Analysis from the PLUDO PR21 Trial of Lutetium-177 vs. Docetaxel - Kim Chi
ABBV-969 Dual-Targeted ADC in Heavily Pretreated mCRPC - Tanya Dorff
Navigating Treatment Decisions in Castration-Resistant Prostate Cancer - Karim Fizazi
The MEVPRO-2 Phase 3 Trial of Mevrometostat plus Enzalutamide in ARPI-Naive mCRPC - Neal Shore
STEAP1-Targeted T-Cell Engager Combined with Abiraterone in the XALience Study - Tanya Dorff
Prior Therapy, Genomics, and Patient Factors in mCRPC Treatment Selection - Kristine Lacuna
PROSTest mRNA Assay Tested for Response Prediction to Lutetium PSMA in mCRPC - Mark Kidd
Radiographic Progression-Free Survival and Overall Survival Correlation in TALAPRO-2 - Neeraj Agarwal
MEVPRO-1 and MEVPRO-2 Trials of EZH2 Inhibitor Mevrometostat in mCRPC - Neeraj Agarwal
Radioligand Therapy and Patient Selection Criteria for Lu-PSMA-617 - Phillip Koo
ProTACT Trial Investigates Next-Generation PSMA-Targeted Alpha Therapy for mCRPC - Aaron Hansen
Phase I PAnTHA Study Evaluates PSMA-Targeted Actinium-225 in mCRPC Patients - Fred Saad
CIPHER Trial Investigates Carboplatin in mCRPC Patients with HRR Mutations - Atul Batra
PEACE-3 Trial Evaluates Radium-223 Plus Enzalutamide in Bone-Metastatic mCRPC - Enrique Gallardo Diaz
BRCAAway Trial Investigates Combination Versus Sequencing of ARPI and PARP Inhibitor in mCRPC - Maha Hussain
EZH2 Inhibition Combined with ARPI Evaluated in Patients with Castration-Resistant Prostate Cancer - Nobuaki Matsubara
Real‑World Use of Radium‑223 in Veterans with Metastatic CRPC: A National Analysis - Martin Schoen
Real-World Analysis of Lutetium-177 in mCRPC by Taxane Treatment Sequence - Micah Ostrowski
ECLIPSE Trial Explores Dosimetry for PSMA-Targeted Therapy in mCRPC - Frankis Almaguel & Jason Hafron
OMAHA-003 Trial Explores CYP11A1 Inhibition in Metastatic Castration-Resistant Prostate Cancer - Evan Yu
A REtrospective Study to Describe the Real-World Treatment Landscape in Patients with Metastatic Castration-Resistant PROstate Cancer: REMPRO - Beyond the Abstract
The PLUDO Study: Comparing First-Line Lutetium vs Docetaxel in Chemo-Naive Metastatic Prostate Cancer - Kim Chi
Biomarker Data from Phase II PT-112 Trial in Heavily Pretreated mCRPC - Alan Bryce
Olaparib Monotherapy or in Combination with Abiraterone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a BRCA Mutation - Beyond the Abstract
Radioligand Therapy Induced DNA Damage Response Kinetics and Biomarker Strategies - Katharina Lückerath & Ken Herrmann
Phase 1 Dosing Strategy and Translational Findings for Investigational Therapy Pasritamig - Karen Autio
Investigational All-in-One CAR T-Cell Platform for Prostate Cancer - Nour Shobaki
Investigational Therapies Target STEAP1 and DLL3 in Advanced Prostate Cancer - Rahul Aggarwal
Investigational RIPTAC™ Therapy (HLD-0915) in Phase I mCRPC Study – Andrew Hahn
Phase 1B Trial Combines Xaluritamig with Hormone Therapy for Metastatic Prostate Cancer - Nicholas Zorko
Targeting NSD2 to Reverse Treatment Resistance in Advanced Prostate Cancer - Jia Li
Targeting SPP1+ Macrophages and the Adenosine Pathway to Boost Prostate Cancer Immunotherapy - Lawrence Fong
ARTISAN Trial: Evaluating Lead-212 PSMA Therapy for Advanced Prostate Cancer - Oliver Sartor
International Analysis of Anti-PD-1/PD-L1 Efficacy and Biomarker Selection in Mismatch Repair-Deficient mCRPC - Niven Mehra
PARP Inhibitors in Prostate Cancer: A Decade of Development and the Combination vs Monotherapy Debate for HRR-Mutated Disease - Neeraj Agarwal
Implementing Lutetium-PSMA — From Trial Design to Operations - Oliver Sartor
Safety and Dosing of Lutetium-PSMA in the Pre-Chemotherapy PSMAfore Trial - Oliver Sartor
Real-World Analysis of Genetic Testing Rates and Barriers in Metastatic Prostate Cancer - Pedro Barata
Integrating PSMA PET Imaging: From Interpretation to Systemic Therapy Selection in Castration-Resistant Prostate Cancer - Oliver Sartor
Results from the Phase 3 PSMAfore Trial in Metastatic Castration-Resistant Prostate Cancer - Karim Fizazi
Pasritamig Bispecific Antibody in Metastatic Castration-Resistant Prostate Cancer - Mark Stein
Phase 1 Trial of an Actinium-Labeled KLK2-Targeting Antibody for mCRPC - Michael Morris
Phase I Study of SYNC-T Combination Therapy for Metastatic Castration-Resistant Prostate Cancer - Jason Hafron
PSMA PET and Radionuclide Therapy in Colombia - Carlos Granados
Development of a Prognostic Model Combining Clinical and Genetic Features in mCRPC - Andrew Armstrong
Overall Survival Results from the TALAPRO-2 Trial in mCRPC Patients - Neeraj Agarwal
Discussion on the Use of Bone Modifying Agents in Metastatic Prostate Cancer - Tian Zhang and Evan Yu
Discussion on Treatment Sequencing for mCRPC After Progression on ADT, ARPI, and Docetaxel - Phillip Kuo & Oliver Sartor